• AZ1497_screen

    Making Medicine Personal in Respiratory Health

    Your health and that of your loved ones is one of the most important aspects of life. It’s also the most important aspect of our work. For more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down.

    Read more »
  • Phil-on-the-Hill-HeaderImage-FINAL

    Asking Congress to Get “ON IT” for Diabetes

    At AstraZeneca, we believe that real progress in improving type 2 diabetes outcomes starts with supporting patients in multiple ways, such as improving access to our medicines, providing educational programs and resources, and advocating on the patient’s behalf, to name a few.

    Read more »
  • Patient doctor

    “I had no idea that there were other forms of constipation” – A Patient’s OIC Story

    For patients with chronic pain, taking a prescribed opioid treatment for long-term pain management may provide pain relief but can also cause opioid-induced constipation (OIC). However, some patients may not realize that constipation is one of the most common side effects of their prescription opioid treatment.

    Read more »
  • christening photo3

    A Patient’s Perspective during Oral, Head and Neck Cancer Awareness Week

    2010 was truly a year that delivered the worst to my life. In April, the unexpected death of my father, a non-smoker, from lung cancer, revealed the mystery of this disease and at times, its unidentifiable origins. Unbelievably, my shock was to be exceeded just nine months after my father’s death when I received the news of my own diagnosis of squamous cell carcinoma.

    Read more »
  • A couple with their dog taking a healthy walk in the wood.

    Why People with Type 2 Diabetes Should Start a Walking Program

    Today, more than 145 million adults in the United States include walking as part of a physically active lifestyle, and this staple exercise continues to grow in popularity. After all, walking can be done just about anywhere and, for most, is as simple as putting one foot in front of the other.

    Read more »
  • AZ1588_Cardiac_regenerating_muscle_cells_screen

    Perspectives on Cardiovascular Disease: A Multi-Faceted Condition

    The 2016 American College of Cardiology (ACC) scientific sessions provides AstraZeneca an opportunity to interact with some of the top clinicians and researchers in the cardiology field, and discuss the difficult clinical questions that they face when treating patients.

    With ACC coming up this weekend, I caught up with Roxana Mehran, MD, of Mount Sinai School of Medicine to discuss the multi-faceted nature of cardiovascular disease (CVD) and how research and science is helping to evolve the way we view the causes and management of CVD.

    Read more »
  • shutterstock_174838673

    Bringing Medical Meetings to Everyone via Social Media

    For decades, medical meetings have been a place for doctors, patients, researchers and advocates to engage with each other and share information about the latest advances in treatments and science. That engagement level has exploded over the last few years, however, with the rise of social media.

    Read more »
  • AZ1465_screen

    How We’re Making Medicine Personal

    At AstraZeneca, we know your health is personal and that’s why we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide to your health and their potential to reduce healthcare spending on other costlier medical procedures. Just as importantly, these decisions enable us to invest in discovering and developing future medicines where new treatments are needed.

    Read more »
  • AstraZeneca Healthcare Foundation Connections for Cardiovascular Health Grant Announcements at the Mid Valley YMCA in Van Nuys, CA on February 2, 2016.


©Nancy Newman Photography
(714) 317-1518
NancyNB@earthlink.net

    From the Head to the Heart: Key Learnings to Improve Cardiovascular Health

    Across the country, nonprofit, grassroots organizations conduct innovative programs designed to reduce the impact of the number one cause of death in the U.S., cardiovascular disease. At the AstraZeneca HealthCare Foundation, we seek to improve cardiovascular health by awarding Connections for Cardiovascular HealthSM (CCH) grants to U.S.-based nonprofit organizations conducting health programs at the community level.

    Read more »
  • ONIT-AZHC-BannerImage-1000x400

    Dr. Phil’s 6 Rules to Help Manage Type 2 Diabetes

    With nearly 28 million Americans living with type 2 diabetes and another 86 million at risk for developing it, many are facing hurdles keeping them from committing to a plan and could use some guidance they can easily reference to stay on track with their health.

    With this in mind, AstraZeneca’s ON IT Movement seeks to empower adults living with type 2 diabetes to make a personal commitment to live a healthier life.

    Read more »

AstraZeneca News

shutterstock_174838673

Bringing Medical Meetings to Everyone via Social Media

For decades, medical meetings have been a place for doctors, patients, researchers and advocates to engage with each other and share information about the latest advances in treatments and science. That engagement level has exploded over the last few years, however, with the rise of social media.

Patients

AZ1497_screen

Making Medicine Personal in Respiratory Health

Your health and that of your loved ones is one of the most important aspects of life. It’s also the most important aspect of our work. For more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down.

Public Policy

Phil-on-the-Hill-HeaderImage-FINAL

Asking Congress to Get “ON IT” for Diabetes

At AstraZeneca, we believe that real progress in improving type 2 diabetes outcomes starts with supporting patients in multiple ways, such as improving access to our medicines, providing educational programs and resources, and advocating on the patient’s behalf, to name a few.